DOI: 10.36347/sjams.2018.v06i12.015

Pages: 4704-4709

Multiple myeloma (MM) is the 2nd most common haematological malignancy among the elderly. Majority of MM patients develop refractoriness/relapse to conventional agents and in such patients, chemotherapy is one of the treatment options. However, prospective data on DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin) chemotherapy is limited. This phase II prospective study intends to find out the response rate, toxicity and survival outcomes of DCEP infusional chemotherapy in relapsed or refractory MM patients (RRMM) who failed ≥ 2 conventional lines of treatment (including bortezomib and one of the IMiDs). The study period was from January 2012 to December 2013. Twenty one patients were recruited into the study. The median age was 48 years (range 38-63y).